Literature DB >> 17163274

Drug-related problems in the community setting: pharmacists' findings and recommendations for people with mental illnesses.

J Simon Bell1, Paula Whitehead, Parisa Aslani, Andrew J McLachlan, Timothy F Chen.   

Abstract

BACKGROUND AND
OBJECTIVE: Adverse drug events are a leading cause of morbidity in Australia and internationally. People taking psychotropic drugs for mental illnesses may be particularly susceptible. This study aimed to classify and describe pharmacists' Home Medicines Review (HMR) findings and recommendations for people with mental illnesses.
METHODS: This was a descriptive study conducted from March to November 2003. General practitioners and community pharmacists practising in two regions of metropolitan Sydney were invited to participate. General practitioners recruited and referred community-dwelling people with mental illnesses to receive HMRs conducted by accredited pharmacists. Reviewing pharmacists interviewed 49 people in their homes. During the interviews the pharmacists provided drug information, assessed drug knowledge and beliefs, and assessed drug adherence. Pharmacists then produced written referenced reports that outlined drug-, patient- and prescriber-related findings and recommendations. These findings and recommendations were presented to the referring general practitioners at follow-up case conferences. MAIN OUTCOME MEASURES: Drugs were classified using the Anatomical Therapeutic Chemical Classification System. Pharmacists' findings and recommendations were classified using the Clinical Pharmacy Activity Classification System.
RESULTS: The most common types of nervous system drugs taken by people who received a HMR were antidepressants (n = 39.33%), analgesics (n = 29.24%) and antipsychotics (n = 17.14%). Pharmacists reported 403 findings and made 360 recommendations for 49 people, with 90% of recommendations being accepted by the referring general practitioners. The most common findings related to potential adverse drug reactions (n = 53, for 47% of people), suspected adverse drug reactions (n = 48, for 55% of people), potential interactions (n = 30, for 37% of people), and people taking additional drugs unbeknown to their referring general practitioner (n = 26, for 25% of people). The most common recommendations were to switch a drug (n = 37, for 49% of people), suggest a non-drug treatment (n = 29, for 41% of people) and to suggest a new drug (n = 27, for 49% of people). At the time of referral, general practitioners documented people to be taking 7.8 +/- 4.4 (mean +/- SD) drugs each (range 1-18). Following home interviews, pharmacists determined people to be taking 9.1 +/- 4.8 drugs (range 1-20). This difference was statistically significant (p < 0.001).
CONCLUSIONS: Pharmacists identified a high incidence of drug-related problems among people receiving treatment for mental illnesses. Pharmacists also identified a higher incidence of overall drug use than documented by the referring general practitioners. HMRs and case conferences, undertaken collaboratively by general practitioners and pharmacists, may be a useful strategy to identify drug-related problems among people with mental illnesses.

Entities:  

Mesh:

Year:  2006        PMID: 17163274     DOI: 10.2165/00044011-200626070-00003

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  46 in total

Review 1.  Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly.

Authors:  R W Shulman; V Ozdemir
Journal:  Can J Psychiatry       Date:  1997-06       Impact factor: 4.356

Review 2.  Predicting and preventing adverse drug reactions in the very old.

Authors:  Louis Merle; Marie-Laure Laroche; Thierry Dantoine; Jean-Pierre Charmes
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

3.  Impact of coaching by community pharmacists on drug attitude of depressive primary care patients and acceptability to patients; a randomized controlled trial.

Authors:  Oscar Brook; Hein van Hout; Hugo Nieuwenhuyse; Eibert Heerdink
Journal:  Eur Neuropsychopharmacol       Date:  2003-01       Impact factor: 4.600

4.  Care planning and case conferencing. Building effective multidisciplinary teams.

Authors:  R Davis; R Thurecht
Journal:  Aust Fam Physician       Date:  2001-01

5.  Adverse drug events in general practice patients in Australia.

Authors:  Graeme C Miller; Helena C Britth; Lisa Valenti
Journal:  Med J Aust       Date:  2006-04-03       Impact factor: 7.738

Review 6.  Effectiveness of complementary and self-help treatments for anxiety disorders.

Authors:  Anthony F Jorm; Helen Christensen; Kathleen M Griffiths; Ruth A Parslow; Bryan Rodgers; Kelly A Blewitt
Journal:  Med J Aust       Date:  2004-10-04       Impact factor: 7.738

Review 7.  Evaluating the impact of pharmacists in mental health: a systematic review.

Authors:  Patrick R Finley; M Lynn Crismon; A John Rush
Journal:  Pharmacotherapy       Date:  2003-12       Impact factor: 4.705

8.  Impact of a collaborative care model on depression in a primary care setting: a randomized controlled trial.

Authors:  Patrick R Finley; Heidi R Rens; Joan T Pont; Susan L Gess; Clifton Louie; Scott A Bull; Janelle Y Lee; Lisa A Bero
Journal:  Pharmacotherapy       Date:  2003-09       Impact factor: 4.705

Review 9.  Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement.

Authors:  Tim J R Lambert; Leon H Chapman
Journal:  Med J Aust       Date:  2004-11-15       Impact factor: 7.738

10.  The Pharmaceutical Benefits Scheme 2003-2004.

Authors:  Ken J Harvey
Journal:  Aust New Zealand Health Policy       Date:  2005-01-12
View more
  17 in total

Review 1.  A systematic review of hospitalization resulting from medicine-related problems in adult patients.

Authors:  Abdullah Al Hamid; Maisoon Ghaleb; Hisham Aljadhey; Zoe Aslanpour
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

2.  An expert panel assessment of comprehensive medication reviews for clients of community mental health teams.

Authors:  Natasa Gisev; J Simon Bell; Claire L O'Reilly; Alan Rosen; Timothy F Chen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-10-15       Impact factor: 4.328

Review 3.  Application of drug-related problem (DRP) classification systems: a review of the literature.

Authors:  Benjamin J Basger; Rebekah J Moles; Timothy F Chen
Journal:  Eur J Clin Pharmacol       Date:  2014-05-02       Impact factor: 2.953

Review 4.  Medication review and reconciliation with cooperation between pharmacist and general practitioner and the benefit for the patient: a systematic review.

Authors:  Marlies M E Geurts; Jaap Talsma; Jacobus R B J Brouwers; Johan J de Gier
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

5.  Drug related problems after discharge from an Australian teaching hospital.

Authors:  Glena R Ellitt; Ellinor Engblom; Parisa Aslani; Tommy Westerlund; Timothy F Chen
Journal:  Pharm World Sci       Date:  2010-06-26

6.  Pharmacist-Led Home Medicines Review and Residential Medication Management Review: The Australian Model.

Authors:  Timothy F Chen
Journal:  Drugs Aging       Date:  2016-03       Impact factor: 3.923

7.  Exploring Community Pharmacist's Knowledge, Attitude, and Practice toward the Provision of Pharmaceutical Care. A Prospective Cross-sectional Study from Saudi Arabia.

Authors:  Abubakar Siddique; Ejaz Ahmed; Mohammed Al Zoghabi; Emad Alsaif; Faisal Alhawshani
Journal:  J Pharm Bioallied Sci       Date:  2022-05-19

8.  The Time is Now for Mental Health Care: Evaluating the Impact of a Clinical Pharmacist on an Acute Mental Health Unit.

Authors:  Amy Soubolsky; Katelyn Halpape
Journal:  Can J Hosp Pharm       Date:  2022-10-03

9.  Drug-related problems among community-dwelling older adults in mainland China.

Authors:  Jiadan Yang; Long Meng; Yu Liu; Liping Lv; Shusen Sun; Rui Long; Xuefeng Shan; Jie Song; Feng Qiu
Journal:  Int J Clin Pharm       Date:  2018-01-16

Review 10.  New roles for pharmacists in community mental health care: a narrative review.

Authors:  Maria Rubio-Valera; Timothy F Chen; Claire L O'Reilly
Journal:  Int J Environ Res Public Health       Date:  2014-10-21       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.